All of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the ...
Investor's Business Daily on MSN2d
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.
Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the ...
CENTERSTONE is the first global Phase III study to show a transmission reduction benefit with an antiviral used in the treatment of a respiratory viral illness. This new data may add to the benefits ...
SWANTON — Three alumni from graduating classes in the 1990s and early 2000s were inducted into the Missisquoi Valley Union ...
Subcutaneous ocrelizumab and hyaluronidase (Ocrevus Zunovo) was approved for relapsing and progressive multiple sclerosis, ...
The action-packed BlackStars Experience, which includes a full day summit and awards will take place in New York City on ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback